CA2546200A1 - Compositions d'administration medicamenteuse transdermique renfermant de l'olanzapine - Google Patents

Compositions d'administration medicamenteuse transdermique renfermant de l'olanzapine Download PDF

Info

Publication number: CA2546200A1
Authority: CA; Canada
Prior art keywords: olanzapine; drug delivery; transdermal drug; composition according; delivery composition
Prior art date: 2003-11-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002546200A

Other languages

English (en)

Inventor

Ryan D. Gordon

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

3M Innovative Properties Co

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-18

Filing date

2004-11-02

Publication date

2005-06-02

2004-11-02 Application filed by Individual filed Critical Individual

2005-06-02 Publication of CA2546200A1 publication Critical patent/CA2546200A1/fr

Status Abandoned legal-status Critical Current

Links

KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 title claims abstract description 110
229960005017 olanzapine Drugs 0.000 title claims abstract description 109
239000000203 mixture Substances 0.000 title claims abstract description 70
238000013271 transdermal drug delivery Methods 0.000 title claims description 36
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 26
239000004820 Pressure-sensitive adhesive Substances 0.000 claims abstract description 14
239000002904 solvent Substances 0.000 claims abstract description 14
239000003961 penetration enhancing agent Substances 0.000 claims abstract description 10
150000003839 salts Chemical class 0.000 claims abstract description 9
238000011282 treatment Methods 0.000 claims abstract description 9
201000000980 schizophrenia Diseases 0.000 claims abstract description 7
206010026749 Mania Diseases 0.000 claims abstract description 6
229920001577 copolymer Polymers 0.000 claims description 40
DXPPIEDUBFUSEZ-UHFFFAOYSA-N 6-methylheptyl prop-2-enoate Chemical compound CC(C)CCCCCOC(=O)C=C DXPPIEDUBFUSEZ-UHFFFAOYSA-N 0.000 claims description 23
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 19
239000000178 monomer Substances 0.000 claims description 18
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 16
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 16
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 13
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 13
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 13
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 13
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 13
239000005642 Oleic acid Substances 0.000 claims description 13
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 13
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 13
235000021122 unsaturated fatty acids Nutrition 0.000 claims description 12
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 11
150000001412 amines Chemical class 0.000 claims description 11
150000004670 unsaturated fatty acids Chemical class 0.000 claims description 11
238000000034 method Methods 0.000 claims description 9
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 8
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical group CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 claims description 8
239000004310 lactic acid Substances 0.000 claims description 8
235000014655 lactic acid Nutrition 0.000 claims description 8
229940048866 lauramine oxide Drugs 0.000 claims description 8
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 7
OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 7
239000002202 Polyethylene glycol Substances 0.000 claims description 6
229920001223 polyethylene glycol Polymers 0.000 claims description 6
GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 claims description 5
230000001225 therapeutic effect Effects 0.000 claims description 5
CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 claims description 4
239000012458 free base Substances 0.000 claims description 3
230000037317 transdermal delivery Effects 0.000 claims description 2
WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 claims 2
125000005314 unsaturated fatty acid group Chemical group 0.000 claims 1
208000020016 psychiatric disease Diseases 0.000 abstract description 3
239000000243 solution Substances 0.000 description 48
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
239000011550 stock solution Substances 0.000 description 26
238000010998 test method Methods 0.000 description 20
239000008199 coating composition Substances 0.000 description 19
238000002156 mixing Methods 0.000 description 17
239000011521 glass Substances 0.000 description 15
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 13
238000000576 coating method Methods 0.000 description 12
230000001186 cumulative effect Effects 0.000 description 11
229940079593 drug Drugs 0.000 description 11
239000003814 drug Substances 0.000 description 11
-1 sorbitan ester Chemical class 0.000 description 11
239000011248 coating agent Substances 0.000 description 10
229920001296 polysiloxane Polymers 0.000 description 10
238000001914 filtration Methods 0.000 description 9
230000004907 flux Effects 0.000 description 9
239000012047 saturated solution Substances 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
239000012046 mixed solvent Substances 0.000 description 8
239000003623 enhancer Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 6
239000004698 Polyethylene Substances 0.000 description 6
239000012530 fluid Substances 0.000 description 6
229920000573 polyethylene Polymers 0.000 description 6
229920000642 polymer Polymers 0.000 description 6
238000002360 preparation method Methods 0.000 description 5
239000000654 additive Substances 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
239000000463 material Substances 0.000 description 3
229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
229920000728 polyester Polymers 0.000 description 3
229940068918 polyethylene glycol 400 Drugs 0.000 description 3
239000000126 substance Substances 0.000 description 3
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
DSCFFEYYQKSRSV-UHFFFAOYSA-N 1L-O1-methyl-muco-inositol Natural products COC1C(O)C(O)C(O)C(O)C1O DSCFFEYYQKSRSV-UHFFFAOYSA-N 0.000 description 2
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000004926 polymethyl methacrylate Substances 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
229920002635 polyurethane Polymers 0.000 description 2
239000004814 polyurethane Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000001593 sorbitan monooleate Substances 0.000 description 2
235000011069 sorbitan monooleate Nutrition 0.000 description 2
229940035049 sorbitan monooleate Drugs 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
238000010345 tape casting Methods 0.000 description 2
YTMRCGDXXPVCNT-GOSISDBHSA-N (2r)-n,n-dimethylhexadecan-2-amine oxide Chemical compound CCCCCCCCCCCCCC[C@@H](C)[N+](C)(C)[O-] YTMRCGDXXPVCNT-GOSISDBHSA-N 0.000 description 1
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
AVTLBBWTUPQRAY-UHFFFAOYSA-N 2-(2-cyanobutan-2-yldiazenyl)-2-methylbutanenitrile Chemical compound CCC(C)(C#N)N=NC(C)(CC)C#N AVTLBBWTUPQRAY-UHFFFAOYSA-N 0.000 description 1
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
WYGWHHGCAGTUCH-UHFFFAOYSA-N 2-[(2-cyano-4-methylpentan-2-yl)diazenyl]-2,4-dimethylpentanenitrile Chemical compound CC(C)CC(C)(C#N)N=NC(C)(C#N)CC(C)C WYGWHHGCAGTUCH-UHFFFAOYSA-N 0.000 description 1
WXLPKTIAUMCNDX-UHFFFAOYSA-N 2h-pyran-3-ol Chemical compound OC1=CC=COC1 WXLPKTIAUMCNDX-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
239000004594 Masterbatch (MB) Substances 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
229920002367 Polyisobutene Polymers 0.000 description 1
239000004721 Polyphenylene oxide Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
229920006397 acrylic thermoplastic Polymers 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
235000020661 alpha-linolenic acid Nutrition 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
238000003287 bathing Methods 0.000 description 1
BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000002131 composite material Substances 0.000 description 1
208000012839 conversion disease Diseases 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000007607 die coating method Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
239000004744 fabric Substances 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
239000004811 fluoropolymer Substances 0.000 description 1
229920002313 fluoropolymer Polymers 0.000 description 1
239000000499 gel Substances 0.000 description 1
229920001903 high density polyethylene Polymers 0.000 description 1
239000004700 high-density polyethylene Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
229920000092 linear low density polyethylene Polymers 0.000 description 1
239000004707 linear low-density polyethylene Substances 0.000 description 1
229960004488 linolenic acid Drugs 0.000 description 1
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229920001684 low density polyethylene Polymers 0.000 description 1
239000004702 low-density polyethylene Substances 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000004745 nonwoven fabric Substances 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229920000139 polyethylene terephthalate Polymers 0.000 description 1
239000005020 polyethylene terephthalate Substances 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
238000007639 printing Methods 0.000 description 1
238000010526 radical polymerization reaction Methods 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000007650 screen-printing Methods 0.000 description 1
229950006451 sorbitan laurate Drugs 0.000 description 1
235000011067 sorbitan monolaureate Nutrition 0.000 description 1
229950011392 sorbitan stearate Drugs 0.000 description 1
238000003860 storage Methods 0.000 description 1
ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
229940039925 zyprexa Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

CA002546200A 2003-11-18 2004-11-02 Compositions d'administration medicamenteuse transdermique renfermant de l'olanzapine Abandoned CA2546200A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US52318603P	2003-11-18	2003-11-18
US60/523,186		2003-11-18
PCT/US2004/036439 WO2005049090A2 (fr)	2003-11-18	2004-11-02	Compositions d'administration medicamenteuse transdermique renfermant de l'olanzapine

Publications (1)

Publication Number	Publication Date
CA2546200A1 true CA2546200A1 (fr)	2005-06-02

Family

ID=34619581

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002546200A Abandoned CA2546200A1 (fr)	2003-11-18	2004-11-02	Compositions d'administration medicamenteuse transdermique renfermant de l'olanzapine

Country Status (6)

Country	Link
US (1)	US20070148218A1 (fr)
EP (1)	EP1684734A2 (fr)
JP (1)	JP2007511605A (fr)
AU (1)	AU2004291043A1 (fr)
CA (1)	CA2546200A1 (fr)
WO (1)	WO2005049090A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2041214A4 (fr)	2006-07-10	2009-07-08	Medipacs Inc	Hydrogel époxy super-élastique
EP2227635A2 (fr)	2007-12-03	2010-09-15	Medipacs, Inc.	Dispositif de mesure de fluide
EP2074988B1 (fr)	2007-12-28	2018-03-14	Industrial Technology Research Institute	Composition à libération prolongée et son procédé de fabrication
US9161943B2 (en)	2007-12-31	2015-10-20	Industrial Technology Research Institute	Sustained release composition and manufacturing method thereof
JP5301190B2 (ja) *	2008-03-31	2013-09-25	積水メディカル株式会社	貼付剤
WO2011032011A1 (fr)	2009-09-10	2011-03-17	Medipacs, Inc.	Actionneur à faible encombrement et méthode améliorée d'administration d'agents thérapeutiques commandée par le soignant
JP2011074034A (ja) *	2009-09-30	2011-04-14	Sekisui Medical Co Ltd	貼付剤
US9500186B2 (en)	2010-02-01	2016-11-22	Medipacs, Inc.	High surface area polymer actuator with gas mitigating components
WO2012012417A1 (fr)	2010-07-21	2012-01-26	3M Innovative Properties Company	Compositions adhésives transdermiques, dispositifs et procédés
US8668675B2 (en)	2010-11-03	2014-03-11	Flugen, Inc.	Wearable drug delivery device having spring drive and sliding actuation mechanism
JP2012158572A (ja) *	2011-02-02	2012-08-23	Nitto Denko Corp	貼付製剤の製造方法
EP2847249A4 (fr)	2012-03-14	2016-12-28	Medipacs Inc	Matériaux polymères intelligents contenant un excès de molécules réactives
CN104379139B (zh)	2012-06-20	2016-09-14	久光制药株式会社	贴附剂
US20140093555A1 (en)	2012-09-28	2014-04-03	Nitto Denko Corporation	Patch preparation containing amine oxide
DE102014102400A1 (de) *	2014-02-25	2015-08-27	Reinhard Caliebe	Topische kosmetische oder pharmazeutische Zusammensetzung
JP6459148B2 (ja) *	2015-09-29	2019-01-30	王子ホールディングス株式会社	経皮吸収型製剤
WO2017057541A1 (fr) *	2015-09-29	2017-04-06	王子ホールディングス株式会社	Préparation d'absorption transdermique
WO2018115010A1 (fr)	2016-12-20	2018-06-28	Lts Lohmann Therapie-Systeme Ag	Système thérapeutique transdermique contenant de l'asénapine et un polysiloxane ou un polyisobutylène
ES2769286T3 (es)	2016-12-20	2020-06-25	Lts Lohmann Therapie Systeme Ag	Sistema terapéutico transdérmico que contiene asenapina
JP7069042B2 (ja)	2016-12-28	2022-05-17	久光製薬株式会社	貼付剤
ES2881783T3 (es)	2017-06-26	2021-11-30	Lts Lohmann Therapie Systeme Ag	Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
CN112533593A (zh)	2018-06-20	2021-03-19	罗曼治疗系统股份公司	含有阿塞那平的透皮治疗系统
CA3101420A1 (fr)	2018-06-20	2019-12-26	Lts Lohmann Therapie-Systeme Ag	Systeme therapeutique transdermique contenant de l'asenapine
US20220040194A1 (en)	2018-12-17	2022-02-10	Starton Therapeutics, Inc.	Use of olanzapine for treatment of parp-inhibitor-induced nausea
EP4090333A1 (fr) *	2020-01-13	2022-11-23	Starton Therapeutics, Inc.	Traitement des vomissements et de la nausée avec une dose minimale d'olanzapine
US20240009204A1 (en) *	2020-09-25	2024-01-11	Starton Therapeutics, Inc.	Treatment of Vomiting and Nausea with Minimum Dose of Olanzapine
US11872320B2 (en)	2021-02-25	2024-01-16	Hisamitsu Pharmaceutical Co., Inc.	Method for treating osteoarthritis
WO2023134641A1 (fr) *	2022-01-12	2023-07-20	新领医药技术(深圳)有限公司	Système d'administration par voie transdermique d'olanzapine, son procédé de préparation et son utilisation
EP4721083A2 (fr)	2023-05-26	2026-04-08	Ategenos Pharmaceuticals Inc.	Système d'administration de médicament transdermique et ses utilisations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE24906E (en) *	1955-11-18	1960-12-13		Pressure-sensitive adhesive sheet material
US5223261A (en) *	1988-02-26	1993-06-29	Riker Laboratories, Inc.	Transdermal estradiol delivery system
US5229382A (en) *	1990-04-25	1993-07-20	Lilly Industries Limited	2-methyl-thieno-benzodiazepine
US5817655A (en) *	1991-04-23	1998-10-06	Eli Lilly And Company	Methods of treatment using a thieno-benzodiazepine
US5817656A (en) *	1991-04-23	1998-10-06	Eli Lilly And Company	Mental disorders
US5605897A (en) *	1991-04-23	1997-02-25	Eli Lilly And Company	2-methyl-thieno-benzodiazepine
US5627178A (en) *	1991-04-23	1997-05-06	Lilly Industries Limited	2-methyl-thieno-benzodiazepine
US5817657A (en) *	1991-04-23	1998-10-06	Eli Lilly And Company	Psychoactive substance disorders
EG23659A (en) *	1995-03-24	2007-03-26	Lilly Co Eli	Process and crystal forms of methyl-thieno-benzodiazepine
CR5278A (es) *	1995-03-24	1996-07-04	Lilly Co Eli	Formulacion oral de 2-metil-tieno-benzodiacepina
US5891461A (en) *	1995-09-14	1999-04-06	Cygnus, Inc.	Transdermal administration of olanzapine
ZA978515B (en) *	1996-09-23	1999-03-23	Lilly Co Eli	Intermediates and process for preparing olanzapine
CZ299247B6 (cs) *	1996-09-23	2008-05-28	Eli Lilly And Company	Olanzapin dihydrát D
WO1998037871A1 (fr) *	1997-02-28	1998-09-03	Minnesota Mining And Manufacturing Company	Dispositif transdermique d'administration de testosterone
CA2422267C (fr) *	2000-09-24	2010-02-16	3M Innovative Properties Company	Procede de sechage destine a l'elimination selective de constituants volatils dans des revetements humides
US20020119187A1 (en) *	2000-09-29	2002-08-29	Cantor Adam S.	Composition for the transdermal delivery of fentanyl
MEP23508A (en) *	2003-10-28	2010-06-10	Noven Pharma	Compositions and methods for comtrolling drug loss and delivery in transdermal drug delivery systems

2004
- 2004-11-02 US US10/579,604 patent/US20070148218A1/en not_active Abandoned
- 2004-11-02 EP EP04819044A patent/EP1684734A2/fr not_active Withdrawn
- 2004-11-02 CA CA002546200A patent/CA2546200A1/fr not_active Abandoned
- 2004-11-02 JP JP2006541215A patent/JP2007511605A/ja not_active Withdrawn
- 2004-11-02 WO PCT/US2004/036439 patent/WO2005049090A2/fr not_active Ceased
- 2004-11-02 AU AU2004291043A patent/AU2004291043A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2005049090A2 (fr)	2005-06-02
AU2004291043A1 (en)	2005-06-02
WO2005049090A3 (fr)	2005-09-29
US20070148218A1 (en)	2007-06-28
JP2007511605A (ja)	2007-05-10
EP1684734A2 (fr)	2006-08-02

Legal Events

Date	Code	Title	Description
2010-11-02	FZDE	Discontinued

Publication	Publication Date	Title
CA2546200A1 (fr)	2005-06-02	Compositions d'administration medicamenteuse transdermique renfermant de l'olanzapine
EP0869781B1 (fr)	2003-05-28	Dispositif transdermique destine a l'administration du flurbiprofene
DK2153828T3 (en)	2017-04-10	PREPARATION FOR TRANSDERMAL ADMINISTRATION OF FENTANYL
AU2002215315A1 (en)	2002-06-20	Composition for the transdermal delivery of fentanyl
EP1381352A1 (fr)	2004-01-21	Administration transdermique de fentanyle et de ses analogues
AU2007205756A1 (en)	2007-08-30	Composition for the transdermal delivery of fentanyl
CN101536996A (zh)	2009-09-23	用于经皮传递芬太尼的组合物